Reply to thread

I don’t believe this is about jealousy. The launch of Camzyos was mishandled by the company. It's unrealistic to expect one Salesforce to sell a complex product while anticipating another Salesforce to do the same, yet earn less in salary and bonuses. Some IS TAS rely on their CTAS representatives just to gain access to offices and meet with providers, but they aren't receiving the credit they deserve. While they might earn the district NPRx, if the district fails to meet its goals, the CTAS won't receive any bonus for their collaborative efforts. Additionally, with goals set so high that they seem unattainable, many IS TAS are missing out on bonus opportunities, while some CTAS with limited potential in their territories are benefiting from the efforts of other CTAS in their district without putting in the same level of effort during their workday. Ultimately, if the company aims for all representatives to function as Rare Disease Specialty reps, then all reps should be compensated equally, with realistic goals established and accountability enforced. The structure of this salesforce is completely flawed.